1887

Journal of Medical Microbiology logo

Volume 60, Issue 6

Extended-spectrum β-lactamases of and screened by the VITEK 2 system Free

Abstract

The VITEK 2 automated system (bioMérieux) is one of the most widely used instruments in clinical microbiology laboratories for the identification and evaluation of the susceptibility profiles of bacteria including the detection of extended-spectrum β-lactamases (ESBLs) produced by , and . Currently, the Clinical and Laboratory Standards Institute recommends the use of ESBL confirmatory tests in addition to standard susceptibility testing. In order to evaluate the accuracy of VITEK 2-positive results regarding clinical isolates of ( = 110) and ( = 72), four additional ESBL detection systems were compared: the Phoenix Automated Microbiology System (BD Diagnostic Systems) and the MicroScan WalkAway-96 System (Dade Behring), and two manual systems as confirmatory tests, the Etest (AB Biodisk) and double disc diffusion (DDS) test. Epidemiological data regarding the tested strains were also collected and their susceptibility phenotypes were determined. The four methods resulted in concordant results for 126 of the 182 strains. However, the different tests displayed distinct results: the VITEK 2 system was in disagreement in 23.9 % of cases with DDS, in 15.3 % with Etest, in 23 % with the MicroScan WalkAway-96 System and in 23.6 % with the Phoenix Automated Microbiology System. Epidemiological data indicated that the majority of ESBL-positive strains were isolated from patients admitted to internal medicine wards (72.7 %), whilst ESBL-positive isolates were equally distributed between internal medicine wards (45.8 %) and intensive care units (45.8 %). Most of these strains were isolated from urine. In contrast to ESBL-negative isolates, the ESBL-positive strains displayed multiple drug resistance, namely to quinolones, aminoglycosides and trimethoprim–sulfamethoxazole. No significant resistance to carbapenems was detected. Overall, this study demonstrates the need for a confirmatory test following positive ESBL detection with the VITEK 2 system (panel AST-037), which appears to yield a large number of false-positive results.

  • Received:
  • Accepted:
  • Published Online:
© 2011 SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.024075-0
2011-06-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/6/756.html?itemId=/content/journal/jmm/10.1099/jmm.0.024075-0&mimeType=html&fmt=ahah

References

  1. Bell J. M., Chitsaz M., Turnidge J. D., Barton M., Walters L. J., Jones R. N. 2007; Prevalence and significance of a negative extended-spectrum β-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. J Clin Microbiol 45:1478–1482 [View Article][PubMed]
     [Google Scholar]
  2. Bradford P. A. 2001; Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:933–951 [View Article][PubMed]
     [Google Scholar]
  3. Cantón R., Oliver A., Coque T. M., Varela M del C., Pérez-Díaz J. C., Baquero F. 2002; Epidemiology of extended-spectrum β-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period. J Clin Microbiol 40:1237–1243 [View Article][PubMed]
     [Google Scholar]
  4. CLSI (2010). Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement. M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute
  5. Dashti A. A., Jadaon M. M., Habeeb F. M. 2009; Can we rely on one laboratory test in detection of extended-spectrum β-lactamases among Enterobacteriaceae? An evaluation of the Vitek 2 system and comparison with four other detection methods in Kuwait. J Clin Pathol 62:739–742 [View Article][PubMed]
     [Google Scholar]
  6. Fang H., Ataker F., Hedin G., Dornbusch K. 2008; Molecular epidemiology of extended-spectrum β-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 46:707–712 [View Article][PubMed]
     [Google Scholar]
  7. Hoffman C. S., Winston F. 1987; A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli . Gene 57:267–272 [View Article][PubMed]
     [Google Scholar]
  8. Jacoby G. A., Sutton L. 1991; Properties of plasmids responsible for production of extended-spectrum β-lactamases. Antimicrob Agents Chemother 35:164–169[PubMed] [CrossRef]
     [Google Scholar]
  9. Kaye K. S., Engemann J. J., Fraimow H. S., Abrutyn E. 2004; Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 18:467–511, viii [View Article][PubMed]
     [Google Scholar]
  10. Livermore D. M. 1995; β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584[PubMed]
     [Google Scholar]
  11. Mendonça N., Ferreira E., Louro D. ARSIP Participants Caniça M. 2009; Molecular epidemiology and antimicrobial susceptibility of extended- and broad-spectrum β-lactamase-producing Klebsiella pneumoniae isolated in Portugal. Int J Antimicrob Agents 34:29–37 [View Article][PubMed]
     [Google Scholar]
  12. Paterson D. L., Bonomo R. A. 2005; Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18:657–686 [View Article][PubMed]
     [Google Scholar]
  13. Sambrook J., Fritsch E. F., Maniatis T. 1989; Extraction and purification of plasmid DNA. In Molecular Cloning: a Laboratory Manual, 2nd edn. pp. 1.21–1.43 Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
     [Google Scholar]
  14. Spanu T., Sanguinetti M., Tumbarello M., D’Inzeo T., Fiori B., Posteraro B., Santangelo R., Cauda R., Fadda G. 2006; Evaluation of the new VITEK 2 extended-spectrum β-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J Clin Microbiol 44:3257–3262 [View Article][PubMed]
     [Google Scholar]
  15. Stürenburg E., Sobottka I., Feucht H. H., Mack D., Laufs R. 2003; Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum β-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagn Microbiol Infect Dis 45:29–34 [View Article][PubMed]
     [Google Scholar]
  16. Tamayo J., Orden B., Cacho J., Cuadros J., Gómez-Garcés J. L., Alós J. I. 2007; Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid. Rev Esp Quimioter 20:334–338[PubMed]
     [Google Scholar]
  17. Thomson K. S., Cornish N. E., Hong S. G., Hemrick K., Herdt C., Moland E. S. 2007; Comparison of Phoenix and VITEK 2 extended-spectrum-β-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized β-lactamases. J Clin Microbiol 45:2380–2384 [View Article][PubMed]
     [Google Scholar]
  18. Wiegand I., Geiss H. K., Mack D., Stürenburg E., Seifert H. 2007; Detection of extended-spectrum β-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol 45:1167–1174 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.024075-0
Loading
Extended-spectrum β-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system
J. Med. Microbiol. 60, 756 (2011); https://doi.org/10.1099/jmm.0.024075-0
/content/journal/jmm/10.1099/jmm.0.024075-0
/content/journal/jmm/10.1099/jmm.0.024075-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error